Viridian Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Viridian Therapeutics's estimated annual revenue is currently $23.4M per year.
- Viridian Therapeutics's estimated revenue per employee is $125,833
Employee Data
- Viridian Therapeutics has 186 Employees.
- Viridian Therapeutics grew their employee count by 51% last year.
Viridian Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Sr. VP, Head Research | Reveal Email/Phone |
4 | Head Forecasting and Market Insights | Reveal Email/Phone |
5 | Senior Director, Drug Development | Reveal Email/Phone |
6 | Senior Director, Business Development & Strategic Alliances | Reveal Email/Phone |
7 | Senior Director, QC | Reveal Email/Phone |
8 | Associate Director Quality Control | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Director, Medical Device Quality | Reveal Email/Phone |
Viridian Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 29 | 480% | N/A | N/A |
#2 | $1.7M | 11 | 0% | N/A | N/A |
#3 | $2.8M | 18 | 13% | N/A | N/A |
#4 | $70.2M | 453 | -1% | N/A | N/A |
#5 | $1.6M | 10 | -66% | N/A | N/A |
#6 | $3.7M | 24 | -8% | N/A | N/A |
#7 | $2.9M | 29 | -9% | N/A | N/A |
#8 | $3.1M | 20 | 25% | N/A | N/A |
#9 | N/A | 9 | -10% | N/A | N/A |
#10 | $2.5M | 16 | -20% | N/A | N/A |
What Is Viridian Therapeutics?
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colo., with research and development operations in Waltham, Mass.
keywords:N/AN/A
Total Funding
186
Number of Employees
$23.4M
Revenue (est)
51%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Viridian Therapeutics News
This table compares Sera Prognostics and Viridian Therapeutics' revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net...
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of Buy by Analysts. Posted by admin on Apr 12th, 2022.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $46.4M | 186 | -10% | N/A |
#2 | $35.9M | 187 | 32% | N/A |
#3 | $7.5M | 190 | 7% | N/A |
#4 | $58.5M | 197 | 6% | N/A |
#5 | $55.7M | 200 | 10% | N/A |